Other languages Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
25.51 ^USD	0.00%		+0.16%	+58.15%

May. 10	Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 01	North American Morning Briefing : Traders Wait for -2-	DJ

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30
US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week	Apr. 29
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 29
Top Midday Gainers	Apr. 29
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 29
Sector Update: Health Care	Apr. 29
Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical	Apr. 29
Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal	Apr. 29
Sector Update: Health Care	Apr. 29
Japan's Ono Pharmaceutical to buy Deciphera for $2.4 billion	Apr. 29
Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises	Feb. 06
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 06
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib	Jan. 18
Deciphera Pharmaceuticals Partners With Genesis Pharma to Distribute Cancer Drug in 14 European Countries	Jan. 12
GENESIS Pharma and Deciphera Pharmaceuticals, Inc. Announce an Exclusive Distribution Agreement for RIPRETINIB in 14 European Markets in Central and Eastern Europe	Jan. 12
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 08
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18	Jan. 05
Deciphera Pharmaceuticals Insider Sold Shares Worth $259,256, According to a Recent SEC Filing	23-10-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Other languages

Filters